Three‐month Posttreatment Prostate‐specific Antigen Level as a Biomarker

Alex K. Bryant BS , Anthony V. D’Amico MD, PhDPaul L. Nguyen MDJohn P. Einck MDChristopher J. Kane MDRana R. McKay MD,  Daniel R. Simpson MDArno J. Mundt MDJames D. Murphy MDBrent S. Rose MD

Abstract

BACKGROUND

Prostate‐specific antigen (PSA) measurement after definitive radiotherapy (RT) and androgen deprivation therapy for localized prostate cancer has been proposed as an early prognostic biomarker. In the current study, the authors investigated the association between 3‐month post‐RT PSA level and biochemical progression‐free survival (bPFS), prostate cancer‐specific survival (PCSS), and overall survival (OS).

METHODS

A total of 5783 patients with intermediate‐risk or high‐risk localized prostate cancer who were diagnosed between 2000 and 2015 and treated with RT and androgen deprivation therapy were identified from Veterans Affairs data. Patients were divided into groups based on 3‐month post‐RT PSA values: <0.10 ng/mL, 0.10 to 0.49 ng/mL, and ≥0.50 ng/mL. The effect of the 3‐month PSA group on bPFS, PCSS, and OS was evaluated in multivariable Cox models adjusting for potential confounders.

RESULTS

There were 2651 patients with intermediate‐risk and 3132 with high‐risk disease; approximately 11% had a 3‐month PSA level of ≥0.50 ng/mL. A higher 3‐month PSA level was found to be strongly associated with each outcome; compared with patients in the group with a 3‐month PSA value <0.10 ng/mL, the authors noted greater hazards for the patients with a 3‐month PSA value ≥0.50 ng/mL (hazard ratio for bPFS: 5.23; PCSS: 3.97; and OS: 1.50 [P<.001 for all]) and the patients with a 3‐month PSA value of 0.10 to 0.49 ng/mL (hazard ratio for bPFS: 2.41 [P<.001]; PCSS: 2.29 [P<.001]; and OS: 1.21 [P = .003]). When analyzed separately, the 3‐month PSA level was found to be predictive of OS in the high‐risk group (P<.001) but not the intermediate‐risk group (P = .21).

CONCLUSIONS

The 3‐month post‐RT PSA level appears to be a strong prognostic biomarker for bPFS, PCSS, and OS in patients with intermediate‐risk and high‐risk prostate cancer, particularly those with high‐risk disease. The 3‐month PSA measurement may augment clinical decision making and holds promise as a potential surrogate endpoint in clinical trials. Cancer 2018. © 2018 American Cancer Society.

First published: 04 May 2018
https://doi.org/10.1002/cncr.31400

You Might Also Enjoy...

Why Can't I Have an Orgasm?

Everyone deserves a satisfying sex life. And if you can’t orgasm, sexual activity can be frustrating and embarrassing. Instead of suffering in silence, it’s time to learn more about sexual dysfunction and the treatment options to fix it.

What Can I Do About My Impotence?

Struggling to perform in the bedroom is embarrassing. But if you have problems getting or maintaining an erection, you’re not alone. Millions of men suffer from impotence — and treatment can help. Learn what your treatment options are here.

Understanding Male Menopause

Menopause is a process that every woman experiences with age, but did you know hormonal imbalance (and its symptoms) aren’t just a women’s health issue? Male menopause is triggered by low testosterone, and it can impact your life in a number of ways.

How the O-Shot® Can Improve Your Sex Life

Low sex drive. Painful intercourse. Inability to orgasm. Sound familiar? You could be suffering from sexual dysfunction. It’s a real condition, and it’s treatable. Find out how the O-Shot® — a platelet-rich plasma therapy — could help you.

My Hormones Are Out of Balance

Hormones are important chemical messengers in your body. When they’re out of balance, you could experience a range of unpleasant symptoms. Learn the signs of hormone imbalance and what you can do to relieve your symptoms.

Help! I'm Struggling With Low Libido

Low libido can make you feel embarrassed, frustrated, and angry. It’s a common problem, but you don’t have to accept it. Learn more about sexual dysfunction, what causes it, and how you can treat it to revitalize your sex life.